If you’re considering GLP-1 medication for weight loss, you’ve probably seen two names come up repeatedly: semaglutide and tirzepatide. Both are FDA-approved for weight management, both are administered as weekly injections, and both produce significant results. But they’re not the same medication, and the differences matter. Here’s an honest, clinical comparison to help you have a more informed conversation with your provider.
How Each Medication Works
Semaglutide (brand names: Wegovy for weight loss, Ozempic for type 2 diabetes) is a GLP-1 receptor agonist. It mimics the naturally occurring hormone GLP-1, which signals fullness to the brain, slows gastric emptying, and helps regulate blood sugar. It targets one receptor pathway.
Tirzepatide (brand names: Zepbound for weight loss, Mounjaro for type 2 diabetes) is a dual GIP/GLP-1 receptor agonist. It mimics two hormones: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). This dual mechanism provides appetite suppression through two pathways rather than one, which may explain why clinical trials show higher average weight loss with tirzepatide.
Think of it this way: semaglutide turns down your appetite through one dial. Tirzepatide turns down two dials simultaneously.
What the Clinical Trials Show
Head-to-head data between semaglutide and tirzepatide is limited, but we can compare results from their respective pivotal trials:
Semaglutide (STEP trials):
- STEP 1: Participants lost an average of 14.9% of body weight over 68 weeks at the 2.4 mg dose
- About one-third of participants lost 20% or more of their body weight
- Significant improvements in waist circumference, blood pressure, and lipid profiles
Tirzepatide (SURMOUNT trials):
- SURMOUNT-1: Participants lost an average of 15.0% (5 mg dose), 19.5% (10 mg dose), and 20.9% (15 mg dose) of body weight over 72 weeks
- More than half of participants on the highest dose lost 20% or more of their body weight
- Significant improvements in cardiometabolic risk factors across all doses
On average, tirzepatide produces greater weight loss at its higher doses compared to semaglutide. However, individual responses vary significantly. Some patients respond better to semaglutide, and a medication’s effectiveness for you depends on your unique biology.
Side Effect Profiles
Both medications share similar side effects because they work through overlapping mechanisms. The most common side effects for both include:
- Nausea (especially during dose escalation)
- Vomiting
- Diarrhea
- Constipation
- Abdominal pain
- Injection site reactions
These gastrointestinal side effects are typically mild to moderate, occur most often during the first few weeks and during dose increases, and tend to improve over time. Both medications use a gradual dose titration schedule specifically to minimize these effects.
In clinical trials, the rates of GI side effects were broadly similar between the two medications, though some analyses suggest tirzepatide may cause slightly less nausea at comparable levels of efficacy. Both medications carry rare but serious warnings for pancreatitis, gallbladder problems, and thyroid tumors (observed in animal studies).
Dosing and Administration
Semaglutide is titrated from 0.25 mg weekly up to a maximum of 2.4 mg weekly for weight management. The full titration typically takes about 16 to 20 weeks.
Tirzepatide starts at 2.5 mg weekly and can be titrated up to 15 mg weekly. The titration period is similar, roughly 16 to 20 weeks to reach the maintenance dose.
Both are subcutaneous injections administered once weekly using pre-filled pens. The injection process is essentially identical for both medications.
Cost Considerations
Without insurance, both medications carry significant retail costs, often exceeding $1,000 per month at brand-name pricing. However, compounded versions may be available at substantially lower costs through licensed pharmacies, depending on current FDA regulations and drug shortage status.
Your provider can discuss the most cost-effective options based on your insurance coverage, available manufacturer coupons, and compounding pharmacy availability. Cost should be part of the conversation, not an afterthought.
Which One Should You Choose?
This isn’t a decision to make on your own. Your healthcare provider will recommend a medication based on:
- Your specific health conditions (tirzepatide may have advantages for patients with type 2 diabetes due to its dual mechanism)
- Your weight loss goals and how much weight you need to lose
- Your tolerance for potential side effects
- Your insurance coverage and budget
- Whether you’ve tried one medication previously without adequate results
Neither medication is universally “better.” Semaglutide has a longer track record and more published long-term safety data. Tirzepatide shows higher average weight loss in trials. Both are effective, safe when prescribed appropriately, and represent a genuine advancement in weight management.
The Bottom Line
Semaglutide and tirzepatide are both highly effective GLP-1 medications for weight loss, but they differ in mechanism, average efficacy, and cost. The right choice depends on your individual health profile, goals, and circumstances. The most important step is having an informed conversation with a qualified provider who can evaluate which option makes the most sense for you.
Want to find out which medication might be right for your situation? Start with Harbor Healthcare’s free assessment and speak with a licensed provider.